论文部分内容阅读
为了解低出生体重儿(LBWI)生后维生素K情况及治疗后的变化,将50例LBWI随机分为A组(26例)和B组(24例)。两组于生后维生素K治疗前采静脉血检测血浆维生素K缺乏诱导蛋白Ⅱ(PIVKA-Ⅱ)后,A组静注维生素K_11mg,B组静注5mg并于5天后再次采血检测PIVKA-Ⅱ。结果显示A、B组LBWI生后各有8例PIVKA-Ⅱ≥2μg/ml(P>0.05)。经维生素K_1治疗后PIVKA-Ⅱ≥2μg/ml各为2例和1例。两组间统计学处理差异不明显(P>0.05)。但维生素K_1治疗前、后PIVKA-Ⅱ≥2μg/ml分别为16例、3例。统计学处理差异显著。本组LBWI观察期间无一例临床出血病例发生。结论:LBWI生后存在维生素K缺乏。静注维生素K_11mg、即可预防维生素K缺乏的发生。
To understand the postnatal vitamin K status in low birth weight infants (LBWI) and the changes after treatment, 50 LBWI patients were randomly divided into A group (26 cases) and B group (24 cases). After intravenous vitamin K deficiency induction of protein Ⅱ (PIVKA-Ⅱ) in both groups before and after vitamin K treatment, intravenous vitamin K_11 mg in group A, intravenous injection of 5 mg in group B and PIVKA-Ⅱ were collected again after 5 days. The results showed that there were 8 cases of PIVKA-Ⅱ≥2μg / ml after LBWI in group A and group B respectively (P> 0.05). After treatment with vitamin K_1 PIVKA-Ⅱ ≥ 2μg / ml each in 2 cases and 1 case. The statistical difference between the two groups was not significant (P> 0.05). However, before and after vitamin K_1 treatment, PIVKA-Ⅱ≥2μg / ml were 16 cases and 3 cases respectively. Statistical differences were significant. No LBNI clinical bleeding in this group occurred during the case. Conclusions: Vitamin K deficiency exists after LBWI. Intravenous vitamin K_11mg, to prevent the occurrence of vitamin K deficiency.